Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2006

View Archived Issues

GI-5005 safe in ongoing phase Ib study in hepatitis C infection

Various doses of cethromycin evaluated in acute bacterial sinusitis

MDX-1303 safe in healthy subjects

HE-2100 increases platelets, neutrophils in healthy volunteers

Further phase II results show efficacy of XP-19986 in GERD

Maintenance of remission assessed with teduglutide in Crohn's disease patients

NS-2330 benefits Parkinson's disease patients in phase II study

Significant clinical improvement in lupus patients treated with IPP-201101

IND-enabling toxicology studies begin for VGX-1027

Avecia and Illumigen sign development and manufacturing agreement for IB-657

Phase I study for i.v. formulation of Portola's ADP receptor antagonist

Arimoclomol receives European orphan drug designation for ALS

ARRY-797 to begin clinical trials for inflammatory disease

CDC to evaluate Novavax's H5N1 pandemic influenza vaccine candidate

BZL-101 cleared to begin phase I/II study for metastatic breast cancer

Sargramostim with rituximab studied for relapsed follicular B-cell lymphoma

Biomira acquires ProlX Pharmaceuticals

MK-2295 studied for proof of concept in postoperative dental pain

Phase IIb 28-day monotherapy trial of SP-01A completes enrollment

TG-100801 for ocular diseases studied in phase I

Panzem NCD studied in phase II for ovarian cancer

AKP-101 manufactured for type 2 diabetes trials

AQ4N studied in phase I/II glioblastoma multiforme trial

New mechanism of action data for rEV-131

Recent patents disclose novel analgesic agents

New agents for treating neurological disorders claimed in recent patents

Novel agents for arrhythmia, hypertension, etc., found in recent patent literature

Novel MDMA derivative increases the duration of L-DOPA's action in a primate model of PD

HepDirect prodrug of prolyl 4-hydroxylase inhibitor may be useful in liver fibrosis

Nerviano identifies potent Aurora kinase inhibitor with promising antitumor activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...